Author

N. Droin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Cell Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 5 Research Focus:cell type annotation· 4 Research Focus:cancer & tumor microenvironment· 3 Research Focus:differential expression· 3 Research Focus:cell signaling & trafficking· 2 Assay:DNA methylation· 2 Approach:biophysical modeling· 1

Frequent Co-Authors

E. Solary· 4 shared A. Imanci· 2 shared A. Renneville· 2 shared D. Selimoglu-Buet· 2 shared f. Porteu· 2 shared L. Laplane· 2 shared M. M. Patnaik· 2 shared M. Morabito· 2 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

E. Solary

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

CXCL8 secreted by immature granulocytes inhibits wildtype hematopoiesis in chronic myelomonocytic leukemia

P. Deschamps, M. Wacheux, A. Gosseye, M. Morabito, A. Pages, A.-M. Lyne, A. Alfaro, P. Rameau, A. Imanci, R. Chelbi, V. Marchand, A. Renneville, M. M. Patnaik, V. Lapierre, B. Badaoui, , D. Selimoglu-Buet

The paper identifies CXCL8 secreted by immature granulocytes as a factor inhibiting wildtype hematopoiesis in CMML, suggesting CXCL8 blockade could slow disease progression.

bioRxiv · Mar 8, 2024Cancer Biology

Targeting Heterochromatin Eliminates Malignant Stem Cells in Chronic Myelomonocytic Leukemia Through Reactivation of Retroelements and Innate Immune pathways

D. Hidaoui, A. Porquet, R. Chelbi, M. Bohm, A. Polizou, V. Alcazer, S. Depil, A. Imanci, M. Morabito, A. Renneville, D. Selimoglu-Buet, S. Thepot, R. Itzykson, L. Laplane, N. Droin, , F. PORTEU

This study shows that combining DNA hypomethylating agents with H3K9me2 inhibitors reactivates immune pathways and eliminates malignant stem cells in CMML by targeting heterochromatin disorganization.

bioRxiv · Feb 2, 2024Cancer Biology

ANKRD26 is a new regulator of type I cytokine receptor signaling in normal and pathological hematopoiesis

H. Raslova, F. Basso-Valentina, A. Donada, V. T. Manchev, M. Lisetto, N. Balayn, J.-E. Martin, D. Muller, C. P. Marin Oyarzun, H. Duparc, B. Arkoun, A. Cumin, N. Droin, L. Faivre, I. Biunno, , R. Favier

This study identifies ANKRD26 as a regulator of type I cytokine receptor signaling in hematopoiesis, showing its role in progenitor proliferation and differentiation.

bioRxiv · Sep 1, 2022Cell Biology

An adaptive pre-DNA-damage-response protects genome integrity

S. Ragu, G. Matos-Rodrigues, N. Droin, A. Barascu, S. Caillat, G. Zarkovic, C. Siberchicot, E. Dardillac, C. Gelot, J. P. Radicella, A. A. Ishchenko, J.-L. Ravanat, E. Solary, B. S. Lopez

The paper identifies a pre-DDR response in human fibroblasts that protects genome integrity without arresting cell cycle progression by managing ROS levels below a stress threshold.

bioRxiv · May 13, 2020 · PreprintCell Biology

RAS mutations drive proliferative chronic myelomonocytic leukemia via activation of a novel KMT2A-PLK1 axis

R. M. Carr, D. Vorobyev, T. Lasho, D. L. Marks, E. J. Tolosa, A. Vedder, L. Almada, A. Yurchenko, I. Padioleau, B. Alver, G. Coltro, M. Binder, S. L. Safgren, I. Horn, X. You, , M. M. Patnaik

This study identifies RAS mutations as drivers of proliferative CMML through a novel KMT2A-PLK1 axis, showing PLK1 inhibition can improve disease outcomes in patient-derived xenografts.

bioRxiv · Dec 23, 2019 · PreprintCancer Biology